Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zuranolone - SAGE Therapeutics

Next Previous
Drug Profile

Zuranolone - SAGE Therapeutics

Alternative Names: S 812217; SAGE 217

Latest Information Update: 03 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SAGE Therapeutics
  • Developer SAGE Therapeutics; Shionogi
  • Class Antidepressants; Antiepileptic drugs; Antiparkinsonians; Cyclopentanes; Mood stabilisers; Nitriles; Phenanthrenes; Pyrazoles; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Seizures

Highest Development Phases

  • Phase III Insomnia; Major depressive disorder; Postnatal depression
  • Phase II Bipolar depression; Essential tremor; Parkinson's disease
  • Preclinical Dyskinesias
  • No development reported Seizures

Most Recent Events

  • 19 Dec 2019 Sage Therapeutics suspends patient enrolment in the phase III REDWOOD trial for Major depressive disorder in USA evaluating potential amendments to the study (PO) (NCT04007367)
  • 05 Dec 2019 Safety and efficacy data from the MOUNTAIN trial for Major depressive disorder released by Sage Therapeutics
  • 02 Oct 2019 Sage Therapeutics completes enrolment in the phase III MOUNTAIN trial for Major depressive disorder in USA (NCT03672175)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top